Tarsus Pharmaceuticals, Inc. (TARS) Cash Flow Statement
Tarsus Pharmaceuticals, Inc. (TARS) generated $74.2M of operating cash flow over the twelve months to 2026-06-30, spent $18.2M on capital expenditure and had free cash flow of $56.0M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TARSTarsus Pharmaceuticals, Inc.Follow TARS — free
—
Price chart with a free account
- Market cap
- 3.0B
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 3.7 | -49.0 | -117.5 | -83.0 | -12.5 | 74.2 | |
| Capital expenditure | 0.6 | 0.5 | 1.5 | 1.6 | 9.9 | -18.2 | |
| Free cash flow | 3.2 | -49.5 | -119.0 | -84.6 | -22.3 | 56.0 | |
| Stock-based compensation | 8.5 | 13.5 | 19.8 | 27.8 | 41.7 | — |
USD millions · SEC XBRL
Tarsus Pharmaceuticals, Inc. — questions
- What is Tarsus Pharmaceuticals, Inc.'s operating cash flow?
- $74.2M over the twelve months to 2026-06-30.
- How much does Tarsus Pharmaceuticals, Inc. spend on capital expenditure?
- $18.2M over the twelve months to 2026-06-30.
- What is Tarsus Pharmaceuticals, Inc.'s free cash flow?
- $56.0M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Tarsus Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.